$PTLA Headlines Results from study of Portola's factor Xa

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$PTLA Headlines

Results from study of Portola's factor Xa inhibitor antidote presented at ASH 11:27 a.m. Dec. 9, 2013 - Seeking Alpha
Portola Pharma Reports New Phase 2 Results Confirming Immediate, Dose-Dependent, Well-Tolerated Reversal of Anticoagulation Activity of XARELTO 10:05 a.m. Dec. 9, 2013 - benzinga.com
ASH Conference: 3 Companies To Watch 10:53 a.m. Dec. 8, 2013 - Seeking Alpha
A Chart You Should See: Biotech IPO Class of 2013 Is Lagging 9:42 a.m. Nov. 26, 2013 - TheStreet.com
Health-Care Stocks: Where to Find Value 6:08 a.m. Nov. 12, 2013 - Barrons.com
Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*) 7:03 a.m. Nov. 11, 2013 - benzinga.com
10-Q: PORTOLA PHARMACEUTICALS INC 5:26 p.m. Nov. 6, 2013 - Edgar Online - (EDG = 10Q, 10K)
Portola Pharmaceuticals Inc's CEO Discusses Q3 2013 Results - Earnings Call Transcript 12:23 a.m. Nov. 6, 2013 - Seeking Alpha
Portola Pharmaceuticals: A Biotech Company With Plenty Of Room To Grow 12:18 p.m. Oct. 30, 2013 - Seeking Alpha
Portola Strengthens On Hopes For Cardiovascular Franchise 1:46 p.m. Oct. 21, 2013 - Seeking Alpha
Portola Prices Public Offering - Analyst Blog 4:30 p.m. Oct. 18, 2013 - Zacks.com
Data on Portola's Andexanet Alfa - Analyst Blog 4:30 p.m. Oct. 15, 2013 - Zacks.com
Portola Pharma Issues Results for First Phase 2 Trial Showing Extended Duration Infusion with PRT4445 3:06 p.m. Oct. 14, 2013 - benzinga.com
Update on Portola's Pipeline - Analyst Blog 12:40 p.m. Oct. 14, 2013 - Zacks.com
Portola Pharmaceuticals to Present Preclinical Data on Andexanet Alfa 6:05 a.m. Aug. 29, 2013 - benzinga.com
Portola Pharmaceuticals' CEO Discusses 2Q 2013 Results - Earnings Call Transcript 1:44 p.m. Aug. 16, 2013 - Seeking Alpha
Encouraging Data on Portola's PRT4445 - Analyst Blog 4:20 p.m. July 9, 2013 - Zacks.com
Bayer Announces Positive Phase I Data - Analyst Blog 4:00 p.m. July 8, 2013 - Zacks.com
Portola Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity of Eliquis(R) 5:32 a.m. July 2, 2013 - benzinga.com
Portola Pharmaceuticals: Developing The Novel Therapies In Blood Clot Formation Disorders 3:01 p.m. July 1, 2013 - Seeking Alpha


Portola Pharmaceuticals Announces New Phase 2 Results Confirming Immediate, Dose-Dependent and Well-Tolerated Reversal of Anticoagulation Activity of XARELTO(R) (rivaroxaban) With Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Reversal Agent 11:00 a.m. Dec. 9, 2013 - GlobeNewswire
District Court Ruling, Cash Tender Offers, Celebration Events, Conference Presentations, and Repurchase Programs - Research Report on AstraZeneca, Salix, Health Net, Volcano and Portola 8:00 a.m. Dec. 9, 2013 - PR Newswire
Portola Pharmaceuticals Announces Upcoming Data Presentations on Andexanet Alfa (PRT4445*) and PRT2070 at 55th American Society of Hematology (ASH) Annual Meeting 8:00 a.m. Dec. 3, 2013 - GlobeNewswire
Proposed M&A's, Conference Schedules, Health Awareness Programs, Prestigious Recognitions and FDA Designations - Research Report on Health Management, Acadia, Health Net, NuVasive and Portola 8:00 a.m. Nov. 29, 2013 - PR Newswire
Portola Pharmaceuticals Receives Breakthrough Therapy Designation From FDA for Andexanet Alfa (PRT4445*), Investigational Factor Xa Inhibitor Antidote 8:01 a.m. Nov. 25, 2013 - GlobeNewswire
Disaster Relief Contributions, New Medical Trials, Clinical Results and Employee Incentives - Research Report on UnitedHealth Group, ACADIA, USANA, Portola and Horizon Pharma 8:00 a.m. Nov. 21, 2013 - PR Newswire
Solid Growth Derived from Successful Product Launches and Registrations - Research Report on Volcano, Dr. Reddy's, USANA, Repligen, and Portola 8:11 a.m. Nov. 13, 2013 - PR Newswire
Portola Pharmaceuticals Announces Additional Positive Phase 2 Proof-of-Concept Data for Andexanet Alfa (PRT4445*) 8:01 a.m. Nov. 11, 2013 - GlobeNewswire
Portola Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update 4:00 p.m. Nov. 5, 2013 - GlobeNewswire
Portola Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 2013 7:00 a.m. Oct. 31, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Genetically-Defined Hematologic Cancers 3:00 p.m. Oct. 24, 2013 - GlobeNewswire
Divestiture, Clinical Study Updates, New Drug Application, and Quarterly Report - Research Report on Geron, NPS, Portola, MannKind, and Exact Sciences 7:00 a.m. Oct. 21, 2013 - PR Newswire
PACT, EBAY, AMRN and PTLA added to NASDAQ Active Stock Watch List at GSR 9:10 a.m. Oct. 17, 2013 - ACCESSWIRE
Portola Announces Pricing of Public Offering of Common Stock 7:33 a.m. Oct. 17, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Proposed Offering of Common Stock 5:56 a.m. Oct. 16, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Release of Lock-up Restriction for Common Stock Held by a Director of the Company 4:05 p.m. Oct. 15, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445*) Provides Prolonged Reversal of Anticoagulation Activity of Factor Xa Inhibitor Eliquis(R) 4:05 p.m. Oct. 14, 2013 - GlobeNewswire
Portola Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of PRT2070 7:01 a.m. Oct. 9, 2013 - GlobeNewswire
Vital Therapies, Inc. Expands Board of Directors 5:01 a.m. Sept. 20, 2013 - Marketwire
Portola Pharmaceuticals Announces Participation at Upcoming Investor Conferences 7:01 a.m. Sept. 5, 2013 - GlobeNewswire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bakery China's International Buyer Surge: A 50% Boost

Updated Category News Views 6

Look Who's Lining Up for Chinese Pastries Alright, here we go. China's baking scene is pulling in audiences far and wide, as if the whole world suddenly caught a whiff of their freshest, steaming buns. The 11th Bakery China Autumn, recently wrapped up at the Wuhan International Expo Center, saw a 50% rise in international buyers. This stat gives you that warm and cozy...

Continue Reading
Hospitals Face $392M Squeeze Under Medicare's CJR-X

Updated Category News Views 40

Medicare's CJR-X Challenges Hospitals 2028 is setting up to be a year hospitals across the U.S. remember, not with a smile, but likely with clenched teeth. Medicare's CJR-X model is ready to put about 2,217 hospitals in a financial vise over hip, knee, and ankle replacements. Going into effect on January 1, 2028, this mandate turns health networks' profit dreams into a...

Continue Reading
WareSpace Expands in U.S. with Key Site Acquisitions

Updated Category News Views 28

WareSpace's National Growth Strategy: A New Expansion Chapter They say everything's bigger in Texas, but WareSpace is showing that smaller can be mighty impactful too. With its shrewd acquisition of sites in Houston's Inner Loop and Fremont's Warm Springs corridor, WareSpace is playing it smart, appeasing that roaring demand for tiny but mighty warehouse spaces across...

Continue Reading
Greenberg Traurig's Stars Shine in Delaware's Legal Scene

Updated Category News Views 27

Five Lawyers, One Prestigious List Eating lunch today, I nearly dropped my sandwich when I read that five top-notch attorneys from Greenberg Traurig have snagged spots on Delaware Today's 2026 Top Lawyers List. This isn't your everyday pat on the back; it's Delaware, the heavyweight champ of corporate law, after all. The Legal Eagles of Greenberg Traurig Kicking off this...

Continue Reading
FGII and tZERO Merger Under Scrutiny: Is it Fair?

Updated Category News Views 8

Sitting at the Crossroads of M&A Scrutiny Alright, it's time to put on our skeptical hats. Out in the world of mergers and acquisitions, not every deal glimmers with gold. You've got FG Imperii Acquisition Corp. (NASDAQ: FGII) under the lens, with a merger alongside tZERO Group, Inc. stirring up a storm. The folks over at Monteverde & Associates, an M&A Class Action Firm...

Continue Reading
Xi Jinping's Vision for China's Financial Evolution

Updated Category News Views 145

Xi's Blueprint for Financial Strength Xi Jinping isn't just whistling Dixie when it comes to reshaping China's financial landscape. His vision is about more than pushing paper; it's about embedding honesty, prudence, and traditional values into the very DNA of China's financial sector. When he talks about enhancing both hard and soft power, he’s thinking wider than...

Continue Reading
Coretek Joins CRN's Elite AI Innovators of 2026

Updated Category News Views 26

Coretek's Leap to AI Innovator Status Here we are, folks. Another announcement hits the wires that showcases a company's ascent amid the swelling AI tide. Coretek, hailing from Farmington Hills, managed to snag a spot on CRN's inaugural 2026 AI Innovators list. No small potatoes, if you ask me, considering the competition on this playing field. Why the fuss? It's about...

Continue Reading
MSA Safety's Q3 2026: Strong Sales, Strategic Moves

Updated Category News Views 65

MSA's Stellar Growth Amidst Strategic Shifts Ah, the rush of quarterly results, and today we're eyeballing MSA Safety's third quarter of 2026. If numbers light your fire, MSA's boasting some scorching ones right now. The company's net sales shot up to $536 million—a 15% leap from the previous year. Now, in this dog's game of margins and market maneuvers, that's a solid...

Continue Reading
Yuhang's Innovative Tech: Journalists Get A Front Row Seat

Updated Category News Views 223

A Sneak Peek into Yuhang's Technological Leap Imagine strolling through a place where technology and nature coexist in harmony. That's exactly what journalists from around the globe got to experience during their recent jaunt to Yuhang District in Hangzhou. We're talking about reps from South Korea, Turkey, the U.S., and even Cuba getting a firsthand look at Yuhang's...

Continue Reading
GNSS Simulator Market: $425M by 2031, Key Insight

Updated Category News Views 17

GNSS Simulator Market: Gadgets Meet Growth A market that's been quietly bubbling away on the back burner is about to boil over: The GNSS Simulator Market, pegged at a neat $424.6 million by 2031. Yeah, it might be niche, but those in the know can't get enough of these satellite-signal replicators. Why GNSS Simulators are Crushing It There's a bunch of reasons why GNSS...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating the LBJ Express: A Decade of Transformational Growth

Updated Category News Views 247

LBJ Express: A Milestone in Infrastructure and Mobility The LBJ Express marks a significant milestone, celebrating its tenth anniversary as a transformative project that has improved mobility and fostered economic growth in the region. Originally opened in September 2015, this impressive 13-mile corridor runs from Interstate 35E through to U.S. 75 along the busy...

Continue Reading
Exploring Growth in the Global Cosmetic Manufacturing Sector

Updated Category News Views 276

Understanding the Rising Cosmetic Manufacturing Market As we dive into the world of beauty and aesthetics, one cannot overlook the vast potential within the cosmetic manufacturing industry. A recent report highlights that the global revenue from the cosmetic manufacturing sector is set to experience significant growth, with projections estimating a remarkable valuation of...

Continue Reading
Navigating Market Trends: Liquidity and Buybacks Drive Growth

Updated Category News Views 190

Market Resilience Amid Liquidity and Buyback Activities The current state of the market presents an intriguing picture, balancing risks while feeling surprisingly secure. It's akin to gliding on a fortified layer of fiscal stability, supported by strong monetary influences and persistent retail investments. Recent fluctuations seem to serve merely as a trial of market...

Continue Reading
AirSculpt Technologies Shares Second Quarter Insights

Updated Category News Views 135

AirSculpt Technologies Reports First Quarter Fiscal 2025 Results AirSculpt Technologies, Inc. (NASDAQ:AIRS), recognized as a national leader in premium body contouring procedures, has shared its financial performance for the first quarter. Despite some challenges, the company is poised for future growth as it continues to innovate in the field of body aesthetics....

Continue Reading
Winshear Gold's Significant Move: Earn-In Agreement on TBGP

Updated Category News Views 147

Winshear Gold Corp's Strategic Earn-In Agreement Winshear Gold Corp. (TSXV: WINS) is making waves in the mineral exploration industry with its newly announced agreement concerning the notable Thunder Bay Gold Project (TBGP). The company, headquartered in Vancouver, is set to earn a 100% interest in the expansive 360 square kilometers of the Thunder Bay region, a site that...

Continue Reading